OTCMKTS:MRMD MariMed - MRMD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding MariMed Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.42 0.00 (0.00%) (As of 02/7/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.40▼$0.4450-Day Range$0.36▼$0.5552-Week Range$0.28▼$0.89Volume341,141 shsAverage Volume264,012 shsMarket Capitalization$142.57 millionP/E RatioN/ADividend YieldN/APrice Target$0.85 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesHeadlinesSEC FilingsShort Interest MariMed MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside102.4% Upside$0.85 Price TargetShort InterestHealthy0.00% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings Growth-33.33%From $0.03 to $0.02 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.89 out of 5 stars 3.5 Analyst's Opinion Consensus RatingMariMed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $0.85, MariMed has a forecasted upside of 102.4% from its current price of $0.42.Amount of Analyst CoverageMariMed has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.00% of the outstanding shares of MariMed have been sold short.Short Interest Ratio / Days to CoverMariMed has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MariMed has recently increased by 7.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMariMed does not currently pay a dividend.Dividend GrowthMariMed does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MRMD. Previous Next 1.9 News and Social Media Coverage News SentimentMariMed has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for MariMed this week, compared to 2 articles on an average week.Search Interest3 people have searched for MRMD on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added MariMed to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MariMed insiders have not sold or bought any company stock.Percentage Held by Insiders23.34% of the stock of MariMed is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.27% of the stock of MariMed is held by institutions. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MariMed are expected to decrease by -33.33% in the coming year, from $0.03 to $0.02 per share.Price to Book Value per Share RatioMariMed has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About MariMed (OTCMKTS:MRMD) StockMariMed, Inc. engages in direct owning of cannabis licenses and management of seed-to-sale operations. It focuses on the development, operation, management, and optimization of facilities for the cultivation, production, and dispensing of medicinal and recreational cannabis and cannabis-infused products. The company was founded by Robert N. Fireman and Jon Levine on January 25, 2011 and is headquartered in Norwood, MA.Read More Receive MRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter. Email Address MRMD Stock News HeadlinesFebruary 1, 2023 | finance.yahoo.comMariMed Announces Fourth Quarter 2022 Earnings DateJanuary 24, 2023 | finance.yahoo.comMariMed Closes $35 Million Credit Facility to Accelerate its Strategic Growth PlansFebruary 8, 2023 | Investing Trends (Ad)Huge Upside Potential With "Staggering" Solar DemandGlobal solar demand is "staggering" right now, according to Bloomberg. Solar installations are set to grow 30% this year alone. And the boom is just beginning, with increasing adoption of solar by commercial, non-profit, and public entities. With only 1% of commercial electricity demand served by on-site solar globally, there is HUGE opportunity for growth.January 17, 2023 | finance.yahoo.comMariMed Strengthens Sales, Marketing, and R&D Teams With Senior Executive HiresDecember 21, 2022 | finance.yahoo.comMariMed Adds Candy Cane Flavored Vape Pen To Its InHouse Brand Line-up for the Holiday SeasonDecember 14, 2022 | finance.yahoo.comMariMed Appoints Jon Levine as Interim Chief Executive OfficerDecember 12, 2022 | finance.yahoo.comMariMed Mourns the Passing of Robert Fireman, Chairman, CEO And Cannabis Industry Pioneer and VisionaryDecember 12, 2022 | finance.yahoo.comMariMed searches for new CEO after death of Robert FiremanFebruary 8, 2023 | Investing Trends (Ad)Huge Upside Potential With "Staggering" Solar DemandGlobal solar demand is "staggering" right now, according to Bloomberg. Solar installations are set to grow 30% this year alone. And the boom is just beginning, with increasing adoption of solar by commercial, non-profit, and public entities. With only 1% of commercial electricity demand served by on-site solar globally, there is HUGE opportunity for growth.November 21, 2022 | finance.yahoo.comMariMed Announces Participation In Upcoming ConferencesNovember 21, 2022 | finance.yahoo.comMariMed Announces Participation In Upcoming ConferencesNovember 16, 2022 | finance.yahoo.comMariMed Supports Giving At ThanksgivingNovember 8, 2022 | finance.yahoo.comMariMed Reports Third Quarter 2022 EarningsOctober 25, 2022 | benzinga.comMariMed Enriches Betty's Eddies Line With Cannabis Chews To Empower Libido, Reduce Stress, Improve Sleep & MoreOctober 25, 2022 | finance.yahoo.comAnswering The Demand for Cannabis Products That Meet Evolving Consumer Needs, MariMed Adds New Products To Its Top-Selling Betty’s Eddies Fruit Chews LineOctober 18, 2022 | investorplace.com3 Cannabis Stock Predictions for 2023 - InvestorPlaceOctober 13, 2022 | seekingalpha.comMariMed Stock: Another MSO Overlooked (OTCMKTS:MRMD) - Seeking AlphaOctober 12, 2022 | benzinga.comMariMed Announces Third Quarter 2022 Earnings Date - MariMed (OTC:MRMD) - BenzingaOctober 12, 2022 | finance.yahoo.comMariMed Announces Third Quarter 2022 Earnings DateOctober 5, 2022 | streetinsider.comMariMed, Inc (MRMD) Opens its First Medical Cannabis Dispensary in Maryland - StreetInsider.comOctober 5, 2022 | globenewswire.comMariMed Opens its First Medical Cannabis Dispensary in Maryland, Will Host a Grand Opening Event with Local Officials - GlobeNewswireOctober 5, 2022 | finance.yahoo.comMariMed Opens its First Medical Cannabis Dispensary in Maryland, Will Host a Grand Opening Event with Local OfficialsOctober 1, 2022 | finance.yahoo.comMariMed Inc. (MRMD)September 23, 2022 | streetinsider.comForm DEF 14A MARIMED INC. For: Sep 22 - StreetInsider.comSeptember 14, 2022 | benzinga.comEXCLUSIVE: How To Conquer The Midwest? 4Front, Pharmacann & Marimed Execs Discuss At Benzinga Cannabis C - BenzingaSeptember 13, 2022 | streetinsider.comMariMed, Inc (MRMD) To Launch Award-Winning Brands in Michigan Adult-Use Cannabis Market - StreetInsider.comSeptember 13, 2022 | globenewswire.comMariMed To Launch Award-Winning Brands in Michigan Adult-Use Cannabis Market - GlobeNewswireSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MRMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MariMed and its competitors with MarketBeat's FREE daily newsletter. Email Address MRMD Company Calendar Last Earnings11/15/2021Today2/08/2023Next Earnings (Estimated)3/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Medicinals & botanicals Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:MRMD CUSIPN/A CIK1522767 Webmarimedadvisors.com Phone(617) 795-5140FaxN/AEmployees260Year FoundedN/APrice Target and Rating Average Stock Price Forecast$0.85 High Stock Price Forecast$0.85 Low Stock Price Forecast$0.85 Forecasted Upside/Downside+102.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$7.22 million Net Margins1.79% Pretax Margin13.56% Return on Equity5.18% Return on Assets1.72% Debt Debt-to-Equity Ratio0.45 Current Ratio1.50 Quick Ratio0.83 Sales & Book Value Annual Sales$121.46 million Price / Sales1.17 Cash Flow$0.07 per share Price / Cash Flow5.61 Book Value$0.11 per share Price / Book3.82Miscellaneous Outstanding Shares339,460,000Free Float260,232,000Market Cap$142.57 million OptionableNot Optionable Beta3.06 Key ExecutivesJon R. LevinePresident, CEO, Secretary, Treasurer & DirectorTimothy ShawChief Operating OfficerSusan M. VillareChief Financial OfficerJay O’MalleyVice President-Marketing & Research & DevelopmentRyan CrandallChief Revenue OfficerKey CompetitorsChromaDexNASDAQ:CDXCMind Medicine (MindMed)NASDAQ:MNMDAyr WellnessOTCMKTS:AYRWFMediWoundNASDAQ:MDWDFitLife BrandsOTCMKTS:FTLFView All Competitors MRMD Stock - Frequently Asked Questions Should I buy or sell MariMed stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MariMed in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MRMD shares. View MRMD analyst ratings or view top-rated stocks. What is MariMed's stock price forecast for 2023? 3 Wall Street analysts have issued 1-year price targets for MariMed's stock. Their MRMD share price forecasts range from $0.85 to $0.85. On average, they predict the company's stock price to reach $0.85 in the next twelve months. This suggests a possible upside of 102.4% from the stock's current price. View analysts price targets for MRMD or view top-rated stocks among Wall Street analysts. How have MRMD shares performed in 2023? MariMed's stock was trading at $0.3562 at the beginning of the year. Since then, MRMD shares have increased by 17.9% and is now trading at $0.42. View the best growth stocks for 2023 here. When is MariMed's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023. View our MRMD earnings forecast. How were MariMed's earnings last quarter? MariMed Inc. (OTCMKTS:MRMD) released its quarterly earnings results on Monday, November, 15th. The company reported $0.01 earnings per share (EPS) for the quarter. The company earned $33.21 million during the quarter. MariMed had a net margin of 1.79% and a trailing twelve-month return on equity of 5.18%. What guidance has MariMed issued on next quarter's earnings? MariMed updated its FY 2022 earnings guidance on Monday, November, 21st. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $132.00 million-$135.00 million, compared to the consensus revenue estimate of $135.80 million. What other stocks do shareholders of MariMed own? Based on aggregate information from My MarketBeat watchlists, some companies that other MariMed investors own include KushCo (KSHB), Organigram (OGI), Auxly Cannabis Group (CBWTF), CNBX Pharmaceuticals (CNBX), Supreme Cannabis (SPRWF), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), GB Sciences (GBLX), Medical Marijuana (MJNA) and Smart Cannabis (SCNA). What is MariMed's stock symbol? MariMed trades on the OTCMKTS under the ticker symbol "MRMD." How do I buy shares of MariMed? Shares of MRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is MariMed's stock price today? One share of MRMD stock can currently be purchased for approximately $0.42. How much money does MariMed make? MariMed (OTCMKTS:MRMD) has a market capitalization of $142.57 million and generates $121.46 million in revenue each year. How many employees does MariMed have? The company employs 260 workers across the globe. How can I contact MariMed? MariMed's mailing address is 11 ROYAL ROAD, BROOKLINE MA, 02445. The official website for the company is marimedadvisors.com. The company can be reached via phone at (617) 795-5140 or via email at ir@mattio.com. This page (OTCMKTS:MRMD) was last updated on 2/8/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.